摘要
神经内分泌肿瘤(neuroendocrine neoplasm,NEN)是一组以神经内分泌分化为特征的上皮性肿瘤,最常见的发生部位是胃肠胰。胃肠胰NEN(gastroenteropancreatic NEN,GEP-NEN)起病隐匿,影像学特征不明显,任何分级均可出现远处转移,是临床诊断和治疗的难点。核医学利用放射性核素标记的分子探针,针对GEP-NEN不同的靶点进行显像,提高了病灶的检出率和诊断准确度。本文就生长抑素受体(somatostatin receptor,SSTR)激动剂、SSTR拮抗剂、18F-FDG、18F-DOPA、胰高血糖素样肽-1受体激动剂、趋化因子配体和成纤维细胞活化蛋白抑制剂等核医学分子探针在GEP-NEN的临床应用研究进展作一述评。
Neuroendocrine neoplasms(NENs)are a group of epithelial tumors characterized by neuroendocrine differentiation,the most common type being gastroenteropancreatic NENs(GEP-NENs).GEP-NENs have insidious onset,and their imaging features are not obvious.Distant metastases can occur in GEP-NENs with different degrees of malignancy,leading to difculties in clinical diagnosis and treatment.Based on different targets in GEP-NENs,radionuclide-labeled molecular probes improve the detection rate of lesions and the accuracy of diagnosis.In this paper,we reviewed the research progress of nuclear medicine molecular probes,including somatostatin receptor(SSTR)agonists,SSTR antagonists,18F-FDG,18F-DOPA,glucagon-like peptide-1 receptor agonists,chemokine ligands,and fibroblast-activation-protein inhibitor in the clinical application of GEP-NENs.
作者
刘宇
刘玫汐
朱文佳
霍力
LIU Yu;LIU Meixi;ZHU Wenjia;HUO Li(Department of Nuclear Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100730,China)
出处
《肿瘤影像学》
2022年第3期222-229,共8页
Oncoradiology
基金
国家自然科学基金(82071967)
中国医学科学院医学与健康科技创新工程(CIFMS-2021-I2M-1-025,CIFMS-2021-I2M-1-002,CIFMS-2021-I2M-1-003)
国家重点研发计划(2020YFC2002702)
中国医学科学院罕见病研究中心资助项目(2016ZX310174-4)
清华大学-北京协和医院合作项目(PTQH201906006)。
关键词
胃肠胰神经内分泌肿瘤
分子探针
核医学显像
诊断
Gastroenteropancreatic neuroendocrine neoplasm
Molecular probe
Nuclear medicine imaging
Diagnosis
